Pharmaceutical Market Forecasts: Respiratory, Fibrosis, and Digital Health Segments Project Growth

Recent market research reports highlight growth projections across multiple pharmaceutical segments, with the progressive pulmonary fibrosis market set to expand significantly, the global asthma and COPD drugs market forecast to reach US$ 82.2 billion by 2036, and the Asia Pacific pharma 4.0 market projected to grow at a rapid CAGR.

The progressive pulmonary fibrosis (PPF) market across the seven major markets is forecast to grow from $1.3 billion in 2025 to $2.7 billion in 2035 at a compound annual growth rate (CAGR) of 7.6%. This growth is mainly driven by the launch of Jascayd (nerandomilast) in the five major European markets and Japan, in addition to four new pipeline drugs expected to launch before 2035. In 2025, the PPF market was dominated by a single drug, Boehringer Ingelheim’s Ofev (nintedanib), considered the gold standard disease modifying option. BI’s Jascayd entered the US market in Q4 2025, offering the first novel entrant into a relatively stagnant market. Further approvals in PPF are expected, with admilparant anticipated to launch in 2027 and Tyvaso in 2029, both in the US. Promising pipeline drugs include Bristol Myers Squibb’s admilparant, United Therapeutics’ Tyvaso (treprostinil), Insmed’s treprostinil palmitil, and Avalyn Pharma’s AP-01, offering both oral antifibrotics and inhaled therapies that employ different mechanisms of action. Inhaled delivery is intended to reduce systemic exposure and provides improved tolerability compared to oral antifibrotics.

The global asthma and COPD drugs market is projected to reach US$ 82.2 billion by 2036, growing at a 5.7% CAGR. This market is driven by rising respiratory cases, drug innovation, and improved healthcare access. Bronchodilators accounted for 36.9% of total market share in 2025, making them the largest drug category. Key players in this market include AstraZeneca, GSK, Boehringer Ingelheim Pharmaceuticals, Inc., Novartis AG, Sanofi, Verona Pharma plc, Merck & Co., Inc., Pfizer Inc., and Teva Pharmaceutical Industries Ltd. The market includes bronchodilators, corticosteroids, monoclonal antibodies, mucolytics, antibiotics, and combination therapies. Innovations such as smart inhalers with adherence tracking, soft-mist inhalers, advanced nebulizers, and self-administered biologic injectables are reshaping disease management.

The Asia Pacific pharma 4.0 market size was estimated at USD 3.92 billion in 2025 and is projected to be worth around USD 25.30 billion by 2035, expanding at a CAGR of 20.50% from 2026 to 2035. The market is majorly driven by higher adoption of AI, IoT, and cloud-based solutions for enhanced manufacturing efficiency. It is also propelled by massive investments in digital healthcare, strong government support for AI, and rising demand for personalized medicines. In 2025, the software segment accounted for 55% of the market share, while services held 45%. By technology, AI and ML accounted for 25%, Big Data Analytics held 22%, IoT held 21%, and Blockchain held 13%. By application, Drug Discovery and Development had a 30% share, Manufacturing held 28%, and Supply Chain Management accounted for 22%. By end use, Pharma and Biotech Companies held a 50% share, and Healthcare Providers accounted for 26%. Top companies in this market include Microsoft, IBM, Amazon Web Services, Inc., SAP SE, Oracle, and GE Healthcare.

These forecasts indicate robust growth across diverse areas of the pharmaceutical industry, from innovative drug treatments for respiratory and fibrotic diseases to the digital transformation of pharmaceutical manufacturing and research.